FindTrial
Sign In

Phosphatase & tensin homolog (PTEN) is a tumor supressor gene used in this study as immunohistochemistry marker for detecting loss of PTEN in Atypical Endometrial Hyperplasia and Endometrioid Endometrial Carcinoma

PTEN immunoexpression in Atypical Endometrial Hyperplasia & Endometrioid Endometrial Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/053964
Enrollment
40
Registered
2023-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C541- Malignant neoplasm of endometrium

Interventions

Intervention1: NIL: NIL

Sponsors

Jawaharlal Nehru Medical College, Sawangi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cases diagnosed on biopsy or surgical specimen of endometrial carcinoma and hyperplasia with correlating clinicopathological features

Exclusion criteria

Exclusion criteria: Endometrial biopsy with inflammatory histomorphology, deficient clinical data and endometrium without representative histomorphology of precancerous and cancerous lesion

Design outcomes

Primary

MeasureTime frame
Immunohistochemical evaluation of PTEN expression is likely to be useful in screening precancerous hyperplasia lesions & detecting earliest stage of endometrial carcinoma.Timepoint: 2 years—

Secondary

MeasureTime frame
To assess whether PTEN is a feasible marker or not.Timepoint: 2 years—

Countries

India

Contacts

Public ContactGarima chandrakar

Jawaharlal nehru medical college, sawangi wardha

aravani@rediff.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026